Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII-Reference-Cited by-同舟云学术

Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII

Published:2022-08-30 Issue:1 Volume:49 Page:153-172
ISSN:0951-6433
Container-title:BioFactors
language:en
Short-container-title:BioFactors

Author:

Recio‐López Patricia¹,Valladolid‐Acebes Ismael¹,Hadwiger Philipp²,Hossbach Markus²,Krampert Monika²,Prata Carla²,Berggren Per‐Olof¹,Juntti‐Berggren Lisa¹^ORCID

Affiliation:

1. The Rolf Luft Research Center for Diabetes and Endocrinology Karolinska Institutet, Karolinska University Hospital L1 Stockholm Sweden

2. Axolabs GmbH Kulmbach Germany

Funder

AstraZeneca

European Research Council

Novo Nordisk Fonden

Svenska Diabetesstiftelsen

Publisher

Wiley

Subject

Clinical Biochemistry,Molecular Medicine,General Medicine,Biochemistry

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/biof.1885

Reference58 articles.

1. Studies of the Proteins in Human Plasma Very Low Density Lipoproteins

2. Apolipoprotein C-III

3. Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?

4. Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.

5. Apolipoproteins C-I and C-III Inhibit Lipoprotein Lipase Activity by Displacement of the Enzyme from Lipid Droplets

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring apolipoprotein C-III: pathophysiological and pharmacological relevance;Cardiovascular Research;2023-12-01